Uroplasty Expands Marketing Program for Urology Practices
"This is the right time to offer an expanded marketing program to ourfast-growing base of customers," said David B. Kaysen, Uroplasty's Presidentand CEO. "In the quarter ended December 31, 2007 we had over 300 activecustomers in the United States, consisting primarily of urologists andurogynecologists, who purchased our Urgent PC neuromodulation system oradditional lead sets. This represents in excess of a 150% increase from 119active customers we had in our fourth fiscal quarter ended March 31, 2007.Our expanded marketing program gives our customers more options to enhancetheir practice, and market the benefits and availability of the Urgent PCsystem to their patients."
Kaysen continued, "Our focus in the U.S. is to both expand our newcustomer base and increase our revenue from our existing customer base. Webelieve this marketing program, an important part of our growth strategy, willallow our customers to increasingly incorporate the Urgent PC system as partof the treatment option they offer to their patients."
Program participants, working closely with Uroplasty, select a marketingprogram suitable for their practice from a menu of options which includeslocal media print advertising, patient and physician education seminars,direct mail campaign, and local radio advertising. Uroplasty and theparticipant share the marketing program costs in proportion to the benefiteach receives from the program.
About the Urgent PC Neuromodulation System
The Urgent PC neuromodulation system is a proprietary, minimally invasivenerve stimulation device designed for office-based treatment of OAB symptomsof urge incontinence, urinary urgency and urinary frequency. Application ofneuromodulation therapy targets specific nerve tissue and disrupts the signalsthat lead to the symptoms of OAB. Uroplasty sells the Urgent PC system in theUnited States, Canada and countries recognizing the CE mark. Outside of theUnited States, the Urgent PC is also indicated for the treatment of fecalincontinence.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-ownedsubsidiaries in The Netherlands and the United Kingdom, is a medical devicecompany that develops, manufactures and markets innovative proprietaryproducts for the treatment of voiding dysfunctions. Our primary focus is thecommercialization of our Urgent PC system, which we believe is the onlyFDA-approved non-surgical neurostimulation therapy for the treatment ofoveractive bladder (OAB) symptoms. We also offer Macroplastique(R) Implants,a bulking agent for the treatment of urinary incontinence. Please visitUroplasty, Inc. at http://www.uroplasty.com.
The Private Securities Litigation Reform Act of 1995 provides a "safeharbor" for certain forward-looking statements. This press release containsforward-looking statements, which reflect our views regarding future eventsand financial performance. These forward-looking statements are subject tocertain risks and uncertainties, including those identified below, which couldcause actual results to differ materially from historical results or thoseanticipated. The words "aim," "believe," "expect," "anticipate," "intend,""estimate" and other expressions, which indicate future events and trends,identify forward-looking statements. Actual future results and trends maydiffer materially from historical results or those anticipated depending upona variety of factors, including, but not limited to:
You May Also Like